News – Page 461 – Endpoints News

Acelyrin tops its $250M crossover with new $300M cash raise from blue-chip syndicate

3 years ago

In aftermath of lead drug implosion, ObsEva's restructuring claims 70% of its staffers — reaching into the C-suite

3 years ago

Moonshot refresh: Biden calls to cut cancer death rate by at least 50% in 25 years

3 years ago

Updated: Akero says positive PhIIb data buck the gloomy NASH tide, but questions remain on safety front

3 years ago

Eyeing accelerated approval for Duchenne gene therapy, Sarepta hopes to bring in $1B in bid for profitability

3 years ago

FDA schedules joint advisory committee meeting to consider first over-the-counter birth control pill

3 years ago

Adagio adopts new name, adds Covid cocktail candidate in ‘new day’ bid after initial drug development woes

3 years ago

BioMarin says PhIII gene therapy study participant's cancer is unrelated to therapy

3 years ago

Verily hooks $1B round amid C-suite shuffle

3 years ago

The scientist who pioneered KRAS drugs has a new idea about making them more powerful

3 years ago

On heels of positive data for ATTR drug, Alnylam looks to raise more capital — nearly $1B worth

3 years ago

FDA hires new vaccine director, a year after two senior leaders quit in protest

3 years ago

Nimbus clinches $125M raise via big donor-backed private financing round following Bristol Myers' TYK2 approval

3 years ago

Microsoft sinks deeper into drug AI, inks collab with diabetes giant Novo Nordisk

3 years ago

#ESMO22: Amgen drops the detailed deck for KRAS G12C, with eroding data likely to trigger fresh debate

3 years ago

Relay kicks off public offering, seeking $300M after laying out robust ESMO data

3 years ago

In the middle of an R&D shakeup, Novartis makes a $300M investment in early-stage biologics research tech

3 years ago

Biden turns to biotech for his inaugural ARPA-H director

3 years ago

#ESMO22: Grail puts its cancer test to a real world trial — but it's 'not ready for prime time yet'

3 years ago

#ESMO22: 'End of the beginning': As PD-(L)1s press on, how far can combo therapies take immuno-oncology?

3 years ago

Freshly baked: Pretzel Therapeutics takes out the oven mitts to drug diseases in the powerhouse of the cell

3 years ago

#ESMO22: Amgen spotlights confirmatory win for KRAS G12C player Lumakras in lung cancer — but there's plenty more ...

3 years ago

Here's your invitation to this year's Endpoints 11 awards. Let's celebrate the best of biotech together

3 years ago

#ESMO22: Deciphera pins its comeback hopes on improved TGCT data

3 years ago

First page Previous page 458 459 460461462 463 464 Next page Last page